Editing Castrate-Resistant Prostate Cancer (section)

====== Ipilumab ======
* MOA: blockade of the immune checkpoint molecule CTLA-4 (cytotoxic T lymphocyte-associated antigen-4)
* '''CA184-043'''
** Population: 799 patients with mCRPC with progression after docetaxel
** Randomized to ipilimumab vs. placebo
** Resuls:
*** OS not improved in the ipilimumab arm (median OS 11.2 months with ipilimumab vs. 10.0 months with placebo
** Kwon, Eugene D., et al."Ipilimumab versus placebo after radiotherapy in patients with metastatic castration-resistant prostate cancer that had progressed after docetaxel chemotherapy (CA184-043): a multicentre, randomised, double-blind, phase 3 trial." The lancet oncology 15.7 (2014): 700-712.
* Other trial
** Randomized to ipilimumab vs. placebo
** Results:
*** OS not improved in the ipilimumab arm (median OS 28.7 months in the ipilimumab arm vs. 29.7 months in the placebo arm (HR 1.11, P = .3667)).
*** Median progression-free survival was significantly improved - 5.6 months in the ipilimumab arm versus 3.8 with placebo arm (HR 0.67; 95.87% CI, 0.55 to 0.81).
** Beer, Tomasz M., et al."Randomized, double-blind, phase III trial of ipilimumab versus placebo in asymptomatic or minimally symptomatic patients with metastatic chemotherapy-naive castration-resistant prostate cancer." J Clin Oncol 35.1 (2017): 40-47.